FLT1 and melanoma: This finding is particularly relevant since we observed an increase in VEGF‐A secretion by resistant cells, as also reported for melanoma resistant to the BRAFi dabrafenib.21, 22, 23 Moreover, VEGFR‐1 is efficiently stimulated by its exclusive ligand PlGF that can be released by the tumour itself or by cells of the tumour microenvironment.